154 related articles for article (PubMed ID: 36059688)
1. Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary
Yu Y; Yu M; Li Y; Zhou X; Tian T; Du Y; Tu Z; Huang M
Front Oncol; 2022; 12():945620. PubMed ID: 36059688
[No Abstract] [Full Text] [Related]
2. MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer.
Fenor MD; Ruiz-Llorente S; Rodríguez-Moreno JF; Caleiras E; Torrego JC; Sevillano-Fernández E; Navarro P; Yagüe-Fernández M; Amarilla-Quintana S; Barquín A; García-Donas J
Clin Transl Oncol; 2022 Dec; 24(12):2432-2440. PubMed ID: 35994225
[TBL] [Abstract][Full Text] [Related]
3. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
5. Effective Treatment of Lung Adenocarcinoma With a Novel SLC44A1-BRAF Fusion Using Pembrolizumab Followed by Trametinib: A Case Report.
Yasui S; Honda T; Onishi I; Ikeda S; Miyazaki Y
Cureus; 2024 Feb; 16(2):e54739. PubMed ID: 38523924
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1-Rearranged Non-Small Cell Lung Cancer: A Case Report.
Li J; Wang Q; Ge J; Tian Y; Yao W
Oncologist; 2021 Dec; 26(12):e2115-e2119. PubMed ID: 34516041
[TBL] [Abstract][Full Text] [Related]
7. Overcoming resistance to single-agent therapy for oncogenic
Jain P; Silva A; Han HJ; Lang SS; Zhu Y; Boucher K; Smith TE; Vakil A; Diviney P; Choudhari N; Raman P; Busch CM; Delaney T; Yang X; Olow AK; Mueller S; Haas-Kogan D; Fox E; Storm PB; Resnick AC; Waanders AJ
Oncotarget; 2017 Oct; 8(49):84697-84713. PubMed ID: 29156677
[TBL] [Abstract][Full Text] [Related]
8. Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report.
Chou YT; Lin CC; Lee CT; Pavlick DC; Su PL
Front Oncol; 2022; 12():838798. PubMed ID: 35372088
[No Abstract] [Full Text] [Related]
9. Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review.
Fasano M; Della Corte CM; Caterino M; Pirozzi M; Rauso R; Troiani T; Martini G; Napolitano S; Morgillo F; Ciardiello F
Front Med (Lausanne); 2021; 8():652005. PubMed ID: 35155453
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.
Nebhan CA; Johnson DB; Sullivan RJ; Amaria RN; Flaherty KT; Sosman JA; Davies MA
Oncologist; 2021 Sep; 26(9):731-e1498. PubMed ID: 33861486
[TBL] [Abstract][Full Text] [Related]
11. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
12. Diverse
Stangl C; Post JB; van Roosmalen MJ; Hami N; Verlaan-Klink I; Vos HR; van Es RM; Koudijs MJ; Voest EE; Snippert HJG; Kloosterman WP
Mol Cancer Res; 2020 Apr; 18(4):537-548. PubMed ID: 31911540
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
14. Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.
Chung C; Reilly S
Am J Health Syst Pharm; 2015 Jan; 72(2):101-10. PubMed ID: 25550132
[TBL] [Abstract][Full Text] [Related]
15. Trametinib in the treatment of melanoma.
Thota R; Johnson DB; Sosman JA
Expert Opin Biol Ther; 2015 May; 15(5):735-47. PubMed ID: 25812921
[TBL] [Abstract][Full Text] [Related]
16. Trametinib: a MEK inhibitor for management of metastatic melanoma.
Lugowska I; Koseła-Paterczyk H; Kozak K; Rutkowski P
Onco Targets Ther; 2015; 8():2251-9. PubMed ID: 26347206
[TBL] [Abstract][Full Text] [Related]
17. Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months.
Marconcini R; Galli L; Antonuzzo A; Bursi S; Roncella C; Fontanini G; Sensi E; Falcone A
Exp Hematol Oncol; 2017; 6():6. PubMed ID: 28344857
[TBL] [Abstract][Full Text] [Related]
18. Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.
Jang JS; Lee A; Li J; Liyanage H; Yang Y; Guo L; Asmann YW; Li PW; Erickson-Johnson M; Sakai Y; Sun Z; Jeon HS; Hwang H; Bungum AO; Edell ES; Simon VA; Kopp KJ; Eckloff B; Oliveira AM; Wieben E; Aubry MC; Yi E; Wigle D; Diasio RB; Yang P; Jen J
Sci Rep; 2015 May; 5():9755. PubMed ID: 25985019
[TBL] [Abstract][Full Text] [Related]
19. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
20. Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.
Bernocchi O; Sirico M; Corona SP; Strina C; Milani M; Cappelletti MR; Ferrero G; Ziglioli N; Cervoni V; Macchiavelli A; Roviello G; Generali D
Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33669326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]